Viking Therapeutics completes enrollment in a phase I maintenance study of VK2735, testing flexible oral and injectable ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback